Xu Z Y
Cancer Institute, Harbin Medical College.
Zhonghua Zhong Liu Za Zhi. 1990 Sep;12(5):345-7.
In order to search for more efficient effector cells than the classical LAK cells for tumor immunotherapy, antitumor activity of TIL was studied. Although fresh TIL were unable to kill both NK-sensitive K562 and NK-resistant Anip 973 targets, rIL-2 activated TIL from 8 lung carcinoma and 4 gastric cancer patients did express significant cytotoxicity against allogeneic solid tumor targets Antitumor activity of activated TIL was more efficient than that of activated autologous PBL By limiting dilution assay, TIL were shown to have a higher frequency of LAK precursors than PBL.
为了寻找比经典的淋巴因子激活的杀伤细胞(LAK细胞)更有效的效应细胞用于肿瘤免疫治疗,对肿瘤浸润淋巴细胞(TIL)的抗肿瘤活性进行了研究。尽管新鲜的TIL不能杀伤自然杀伤细胞(NK)敏感的K562细胞和NK抵抗的Anip 973细胞,但重组白细胞介素-2(rIL-2)激活的来自8例肺癌患者和4例胃癌患者的TIL对异基因实体瘤靶细胞确实表现出显著的细胞毒性。激活的TIL的抗肿瘤活性比激活的自体外周血淋巴细胞(PBL)更有效。通过有限稀释分析,显示TIL比PBL具有更高频率的LAK前体细胞。